Press Releases

Following the DOJ's lawsuit against Visa for alleged anticompetitive behavior in two debit network services markets, ITIF released the following statement from Joseph V. Coniglio, director of antitrust and innovation.

A 20-month investigation of Chinese innovation capabilities in 10 advanced-technology industries suggests that China has not yet taken the overall lead, but its firms are making rapid progress in developing their innovation capabilities and will likely equal or surpass the U.S. and other Western leaders within a decade or so.

Following the Court of Justice’s decision in the long-running Google Shopping case, ITIF released the following statement from Joseph V. Coniglio, director of antitrust and innovation.

China dominates the field of quantum communication and roughly matches the United States in the field of quantum sensing, although it lags behind in quantum computing, according to a new report from ITIF.

China’s relentless drive and strategic investments in AI, indicate that it is only a matter of time before it matches or surpasses the U.S. capabilities in the field, according to a new ITIF report.

Despite China’s big investments, it’s still years behind in semiconductors—but its rapid IP gains mean the U.S. must act fast on R&D, export controls, and STEM or risk losing its edge.

In response to the lawsuit filed by X against the Global Alliance for Responsible Media, ITIF released the following statement from Vice President Daniel Castro.

Following Illinois Governor J.B. Pritzker signing into law an amendment to the state’s Biometric Information Privacy Act (BIPA), ITIF issued the following statement from Senior Policy Manager Ash Johnson.

Following a ruling by Judge Mehta in the U.S. District Court for the District of Columbia that Google’s browser and Android agreements constituted unlawful monopolization under Sherman Act §2, ITIF released the following statement from Joseph V. Coniglio, director of ITIF’s Schumpeter Project on Competition Policy.

ITIF's new report finds that China's biotech industry is rapidly evolving from copycat to competitor, doubling its clinical trials and securing U.S. FDA approvals, signaling a significant challenge to U.S. leadership in global biotech innovation.